Unicycive Therapeutics Announces Full Year 2023 Financial Results and Provides Business Update

28.03.2024 - – Oxylanthanum Carbonate (OLC) Topline Data Expected in Q2 2024 – – UNI-494 Granted Orphan Drug Designation in Delayed Graft Function of Acute Kidney Injury – – UNI-494 Phase 1 Single Ascending Dose Portion of Clinical Trial Complete – LOS ALTOS, ...

Related Keywords

Sweden ,Long Beach ,California ,United States ,Stockholm ,Shalabh Gupta ,Nasdaq ,Linkedin ,Development Rd Expenses ,Exchange Commission ,National Kidney Awareness Month ,Drug Administration ,Company Or Unicycive ,Unicycive Therapeutics Inc ,Pnational Kidney Foundation Spring Clinical Meeting ,Lotus International ,Youtube ,European Renal Association ,Chief Executive Officer ,New Drug Application ,International Conference ,Critical Care Nephrology ,Year Ended December ,Private Securities Litigation Reform Act ,Risk Factor ,Annual Report ,Unicycive Therapeutics ,